POEMS Syndrome Clinical Trial
Official title:
Evaluation of Efficacy and Safety of Lenalidomide (Revlimid®) in Patients With POEMS Syndrome
Lenalidomide is a immunomodulatory drug derived from thalidomide, without neurotoxicity.
Lenalidomide blocks the increased secretion of interleukin-6, tumor necrosis factor alpha
and vascular endothelial growth factor (VEGF). The association with dexamethasone increased
Lenalidomide response rate.
More recently the efficacy of Lenalidomide has been reported in a patient with POEMS
(POEMS:polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin
changes) syndrome with improvement of clinical condition and reduction of vascular
endothelial growth factor (VEGF) and interleukin-6 (IL-6) level.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06040567 -
Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
|
||
| Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
| Completed |
NCT04396496 -
Treatment of POEMS Syndrome With Daratumumab
|
Phase 2 | |
| Recruiting |
NCT05263817 -
A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
|
Early Phase 1 | |
| Active, not recruiting |
NCT02921893 -
Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome
|
Early Phase 1 | |
| Completed |
NCT01816620 -
Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome
|
Phase 2 | |
| Completed |
NCT02193698 -
Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial
|
Phase 2 | |
| Completed |
NCT01639898 -
POEMS Syndrome Treatment With Lenalidomide
|
Phase 2 | |
| Recruiting |
NCT05476458 -
To Evaluate Efficacy of Red Dichromatic Imaging (RDI) in Achieving Hemostasis During POEM Using GF 1500 UGI Scope
|